PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma

Clin Cancer Res. 2011 Jul 1;17(13):4285-95. doi: 10.1158/1078-0432.CCR-10-3236. Epub 2011 May 24.

Abstract

Purpose: To investigate the molecular mechanisms through which polo-like kinase-1 (PLK1) takes part in anoikis resistance of esophageal squamous cell carcinoma (ESCC) cells.

Experimental design: The role of PLK1 in cell anoikis resistance was examined by ectopic gene expression and siRNA-mediated knockdown. Glutathione S-transferase pull-down and co-immunoprecipitation assays were utilized to investigate PLK1-interacting proteins. Electrophoretic mobility shift assay, chromatin immunoprecipitation, and reporter gene assays were carried out to identify the transcription factors responsible for PLK1 expression during anoikis resistance.

Results: We found that detachment of ESCC cells triggers the upregulation of PLK1. Elevated PLK1 expression contributes to protection against anoikis in cancer cells through the regulation of β-catenin expression. Moreover, we showed that, through direct binding to the PLK1 promoter, the NF-κB subunit RelA transcriptionally activates PLK1, which inhibits the ubiquitination and degradation of β-catenin. Inhibition of the NF-κB pathway restores the sensitivity of cancer cells to anoikis by downregulating PLK1/β-catenin expression. In addition, RelA gene amplification and protein overexpression was significantly correlated with PLK1 expression in ESCC tissues.

Conclusions: Our findings suggest that upregulation of PLK1 triggered by cell detachment is regulated by RelA at the transcriptional level. PLK1 protects esophageal carcinoma cells from anoikis through modulation of β-catenin protein levels by inhibiting their degradation. Taken together, this study reveals critical mechanisms involved in the role of RelA/PLK1/β-catenin in anoikis resistance of ESCC cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anoikis / genetics*
  • Carcinoma, Squamous Cell* / genetics
  • Carcinoma, Squamous Cell* / metabolism
  • Carcinoma, Squamous Cell* / pathology
  • Cell Adhesion / genetics
  • Cell Cycle Proteins / genetics*
  • Cell Line, Tumor
  • Esophageal Neoplasms* / genetics
  • Esophageal Neoplasms* / metabolism
  • Esophageal Neoplasms* / pathology
  • Gene Amplification / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • NF-kappa B / metabolism*
  • Polo-Like Kinase 1
  • Proteasome Endopeptidase Complex / metabolism
  • Protein Serine-Threonine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Signal Transduction / genetics
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism
  • Transcriptional Activation / genetics*
  • Up-Regulation / genetics
  • beta Catenin / metabolism*

Substances

  • Cell Cycle Proteins
  • NF-kappa B
  • Proto-Oncogene Proteins
  • Transcription Factor RelA
  • beta Catenin
  • Protein Serine-Threonine Kinases
  • Proteasome Endopeptidase Complex